Sun Eyes Big Stage For Concert’s Alopecia Asset
Sun's Ilumya And Winlevi Novel Brands Led Growth In Q3
Executive Summary
Sun outlines contours of path ahead for deuruxolitinib, which came to it via the recent $576m Concert deal and pits it against Eli Lilly's Olumiant and Pfizer's investigational candidate ritlecitinib. The Indian firm is believed to have had the JAK 1/2 inhibitor on its radar since August last year.
You may also be interested in...
Generic Revlimid Flounders Amid Successful Q2 Performance At Sun
Sun delivered an exceptional Q2 performance, marred by a 9% decline in its US business due to a significant drop in lenalidomide sales.
FDA Import Alert At Sun’s Site: Here’s The Long And Short Of The Impact
US FDA import alert at Halol site comes as a setback for Sun Pharma, but analysts shrug off wider concerns for now given the low dependence on the facility for future growth. Investors are, however, also tracking the escalated compliance situation for the firm’s Mohali plant, inherited via the Ranbaxy deal.
Revlimid Generic Revs Up Dr Reddy’s To Record Gains, There’s More To Come
Generic Revlimid US sales propel Dr Reddy’s to a record fiscal second quarter, with the management indicating that “meaningful” contributions are likely in the coming months too. The Indian firm also expects to deploy its healthy cash flows for deal-making, aided by tempered valuations in some segments amid geopolitical and economic turbulence.